October 28, 2011SOLVO Biotechnology has expanded its portfolio with highly relevant new uptake inhibition assays, using Metformin as a probe-substrate for MATE1 and OCT1 transporters. Metformin is the most widely-used anti-diabetic drug in the United States. Clinically relevant polymorphisms associated with increased metformin exposure have been shown for both MATE1 and OCT1 transporters. Metformin is a known substrate for both transporters. The Organic Cation Transporter 1 (OCT1) mediate drug uptake into hepatocytes and renal proximal tubular cells as well. Multidrug and Toxin Extrusion Protein 1 (MATE1) is primarily expressed in the kidney and liver, where it is localized to the luminal membranes of the urinary tubules and bile canaliculi. It is a major component of subsequent export of organic cations into bile and urine. OCT1 and MATE1 play an important role in the uptake and transcellular transport of metformin as well. For this reason SOLVO has developed a new validated uptake inhibition assay for OCT1 and MATE1 transporters with the drug substrate metformin to provide even more relevant data for your drug candidate. Besides these new assays SOLVO also offers uptake inhibition assay services on these transporters with TEA (tetraethylammonium) as probe substrate. Learn more about our uptake transport assay services.
Next entry: New Ready-to-use Vesicular Transport Assay Kit